Sphere Fluidics Launches Cyto-Mine Chroma: Revolutionizing Single-Cell Analysis
Leading biotechnology firm Sphere Fluidics unveiled a groundbreaking advancement in single-cell analysis with the introduction of Cyto-Mine Chroma at the SLAS2025 International Conference and Exhibition in San Diego. This innovative platform addresses critical challenges in bioengineering and promises significant improvements in efficiency and precision across diverse applications.
Cyto-Mine Chroma: The Future of Single-Cell Analysis
Cyto-Mine Chroma represents the latest iteration of Sphere Fluidics’ industry-leading Cyto-Mine single-cell analysis platform. Designed for functional cell analysis and isolation, this new tool offers enhanced capabilities that include multiplexing and increased assay flexibility. The platform can screen up to tens of millions of cells per day, a significant improvement over traditional methods.
By integrating a four-color laser and detector system, Cyto-Mine Chroma can analyze more parameters per cell in a single assay. This expanded capability supports the upcoming launch of Sphere Fluidics’ first multiplexed assay kit, which will offer multiple readouts within a single experiment. The result? Optimized throughput and precision, enabling faster project timeline completion and cost savings.
Early Access Program: A Chance to Get Ahead
To provide an opportunity for early testing, Sphere Fluidics is opening its Early Access Program. This program invites pioneering researchers and forward-thinking customers to experience Cyto-Mine Chroma firsthand. Through collaboration, Sphere Fluidics can gather valuable feedback and insights to drive innovation and inform future developments.
Participation in the Early Access Program promises faster project timelines, reduced effort and cost, and a competitive edge in fields such as antibody discovery, cell line development, and cell therapy. It underscores Sphere Fluidics’ commitment to advancing biotechnology and meeting the evolving needs of the industry.
On-Stage Demo at SLAS2025
Sphere Fluidics will showcase the Cyto-Mine Chroma platform at booth #2744 during the SLAS2025 conference. On Tuesday, January 28th, from 12:00 – 12:20 pm, Chief Technology Officer Richard Hammond will present a Solutions Spotlight to demonstrate the platform’s capabilities. This is a must-attend session for anyone interested in the future of single-cell analysis.
The next-generation Cyto-Mine Chroma platform has been designed to transform single-cell analysis. We are excited to unveil this innovative platform and its Early Access Program at SLAS, the premier event for lab automation and screening. This launch underscores our dedication to advancing biotechnology. Collaborating closely with key industry stakeholders and researchers will allow us to ensure our microfluidic technologies meet the evolving needs of the sector, both now and in the future.”
Dale Levitzke, CEO, Sphere Fluidics
The Impact on Biotechnology
The Cyto-Mine Chroma platform marks a significant milestone in the field of single-cell analysis. Its capabilities to multiplex and analyze multiple parameters per cell will enable more precise and efficient research, paving the way for breakthrough discoveries in various scientific disciplines. By accelerating the selection of superior candidate cells for further analysis, this technology promises to streamline processes and reduce costs, leading to faster advancements in biotechnology.
The Early Access Program not only offers a chance to get ahead in the field but also fosters collaboration between Sphere Fluidics and industry experts. This partnership will drive innovation and ensure that the platform meets the needs of the sector, both now and in the future. As the race to discover new therapies and treatments intensifies, tools like Cyto-Mine Chroma will be crucial in accelerating the pace of scientific progress.
Join the Revolution in Single-Cell Analysis
Sphere Fluidics’ launch of Cyto-Mine Chroma marks a significant step forward in biotechnology. With its enhanced capabilities and potential to accelerate research, this platform promises to transform the field of single-cell analysis.
Attendees at SLAS2025 can experience Cyto-Mine Chroma firsthand at booth #2744 and learn more at Richard Hammond’s Solutions Spotlight presentation. Don’t miss this opportunity to join the revolution in single-cell analysis and contribute to the future of biotechnology.
To stay updated on the latest developments from Sphere Fluidics, follow them on social media and sign up for their newsletters. Your support will help drive innovation in this exciting field.
Comments, shares, and subscriptions help our platform grow and bring you more content like this. Feel free to leave your thoughts in the comments below!